Clinical trials: Type 2 Diabetes Treated With Insulin
Metabolism and Nutrition Disorder, Obesity
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin.
- Trial name
- SCALE™ Insulin (NCT02963922)
- Testing
- Liraglutide 3.0 mg
- Where
- 54 sites in United States, Canada and 5 more
- Volunteers
- 396 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Safety and Efficacy of Insulin Aspart in Type 2 Diabetes
This trial is conducted in Japan. The aim of this trial is to investigate the safety and efficacy of NovoRapid® (insulin aspart) as meal time insulin in subjects with type 2 diabetes treated on a basal-bolus regimen with Neutral…
- Trial name
- NCT01649570
- Testing
- insulin aspart
- Where
- Japan
- Volunteers
- 123 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Closing the Loop in Adolescents During Non-compliance Behaviours
The ultimate goal of the investigators ongoing research is the development of a closed-loop system for insulin delivery, which can help people with type 1 diabetes (T1D) attain a tight glucose control avoiding the risk of…
- Trial name
- NCT01629277
- Testing
- Closed-loop, standard insulin pump
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University of Cambridge
Type 2 Diabetes Mellitus Without Insulin Treatment
Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes
A single center, open label, randomized, clinical trial comparing ApoB/ApoA ratio of Vytorin 10/20mg vs atorvastatin 20mg treatment. DM2 patients will be screened for inclusion criteria.
- Trial name
- NCT01185236
- Testing
- simvastatin/ezetimibe, atorvastatin 20mg
- Where
- South Korea
- Volunteers
- 132 people
- Sponsor
- Seoul National University Hospital
Type 2 Diabetes
Clinical Decision Support With Continuous Glucose Monitoring Data for Managing Type 2 Diabetes
The goal of this project is to see if an electronic health record (EHR)-based smart order set with continuous glucose monitoring data to provide decision support can improve blood sugar management in people with type 2 diabetes…
- Trial name
- TRACTION-PC (NCT07394075)
- Testing
- Continuous Glucose Monitoring Clinical Decision Support
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- HealthPartners Institute
Diabetes Type 2, Weight Gain
Effects of Insulin Detemir and NPH Insulin on Renal Handling of Sodium, Fluid Retention, and Weight in Type 2 Diabetic Patients
Hypothesis: Changing type 2 patients treatment from Insulin Insulatard to Insulin Detemir will increase their excretion of sodium in the urine and thereby decrease their extracellular volume and body weight.
- Trial name
- Le-Na (NCT00742976)
- Testing
- Insulin Detemir; Insulin Insulatard, Insulin Detemir, Insulin Insulatard
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Diabetes Mellitus, Type 1, Adrenal Insufficiency
Hypoglycaemia (Low Blood Sugar) in Adults With Diabetes and Adrenal Failure
The purpose of this study is to measure how often low blood sugars occur in people who live with both adrenal insufficiency (AI) and diabetes and need to take insulin.
- Conditions
- Diabetes Mellitus, Type 1, Adrenal Insufficiency, Diabetes Mellitus Type 2 - Insulin-Treated
- Trial name
- HYPO-DIAD (NCT05806190)
- Testing
- Continuous Glucose Monitoring
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- Imperial College Healthcare NHS Trust
Type1 Diabetes Mellitus
A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus
Primary Objective: To demonstrate bioequivalence between insulin glulisine given as 300 Units/mL test formulation and insulin glulisine 100 Units/mL reference formulation after a single subcutaneous (SC) dose.
- Trial name
- NCT02910518
- Testing
- Insulin glulisine (U300), Insulin glulisine, Insulin aspart
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- Sanofi
Diabetes Mellitus Type 2 - Insulin-Treated
Insulin Titration System Based on Deep Learning
This is an open-labeled, one-arm intervention trial to access the effect and safety of the Insulin Titration System Based on Deep Learning in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT05409391
- Testing
- Insulin Titration System
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Shanghai Zhongshan Hospital
Diabetes Mellitus, Type 2
Self-monitoring of Blood Glucose in Insulin-treated Patients With Type 2 Diabetes
Primary Objective: The objective of the study is to investigate the effect of a specific frequency of Self-monitoring of blood glucose (SMBG) on glycemic control and quality of life in patients with type 2 diabetes and who are in…
- Trial name
- NCT01460459
- Testing
- a specific frequency of SMBG
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Medical Research Foundation, The Netherlands
Diabetes Mellitus, Type 1
Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults
This study is a randomized, controlled trial to evaluate the efficacy and safety of the Omnipod® 5 System with the FreeStyle Libre 2 continuous glucose monitor compared to Multiple Daily Injections (MDI) along with the FreeStyle…
- Trial name
- RADIANT (NCT05923827)
- Testing
- Omnipod 5 System
- Where
- 19 sites in Belgium, France and 1 more
- Volunteers
- 189 people
- Sponsor
- Insulet Corporation
Diabetes Mellitus
Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)
The purpose of this study is to test for superiority in improvements from baseline in patient reported outcomes in subjects with type 1 or type 2 diabetes when treated with insulin glargine plus rapid acting insulin glulisine MDI…
- Trial name
- NCT00135941
- Testing
- insulin glargine, insulin glulisine
- Where
- United States
- Volunteers
- 582 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin
This study compares insulin icodec (a new insulin taken once a week) to insulin degludec (an insulin taken once daily which is already available on the market) in people with type 2 diabetes.
- Trial name
- ONWARDS 2 (NCT04770532)
- Testing
- Insulin degludec, Insulin Icodec
- Where
- 88 sites in United States, Bulgaria and 7 more
- Volunteers
- 526 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Evaluation of a Treatment and Education Program for Diabetic Patients Who Use Flash Glucose Monitoring
This study is a randomized, controlled, prospective trial with a 6-month follow- up. A newly developed psychoeducational treatment and education programme for diabetic patients on an insulin therapy who use flash glucose…
- Trial name
- FLASH (NCT03175315)
- Testing
- Treatment and education program for patients with diabetes who use flash glucose monitoring (FLASH)
- Where
- Germany
- Volunteers
- 216 people
- Sponsor
- Norbert Hermanns
Type 2 Diabetes
Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients
Primary objective: To evaluate the effect of lixisenatide versus placebo over a period of 24 weeks on glycemic control, as evaluated by glycosylated hemoglobin (HbA1c) reduction, in older type 2 diabetes participants (T2DM) who…
- Trial name
- GetGoal-O (NCT01798706)
- Testing
- Lixisenatide (AVE0010), Antidiabetic background therapy
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 350 people
- Sponsor
- Sanofi
Type II Diabetes
Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes
The purpose of this study is to assess the 1 month safety and tolerability after multiple oral doses of AZD1656 in patients with Type 2 Diabetes Mellitus Treated with Insulin
- Trial name
- NCT00856908
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes
The purpose of this clinical research study is to learn if BMS-512148, added to insulin and one or two anti-diabetes medications (metformin and/or pioglitazone or rosiglitazone), can help reduce the blood sugar levels compared to…
- Trial name
- NCT00357370
- Testing
- Dapagliflozin
- Where
- 23 sites in United States, Canada
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.
The study aims to evaluate the efficacy and safety of INS068 once daily (QD) in subjects with type 2 diabetes not adequately controlled with basal insulin compared to insulin Glargine QD for 26weeks.
- Trial name
- NCT05702073
- Testing
- INS068 injection, Insulin Glargine
- Where
- China
- Volunteers
- 423 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes Mellitus
Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes
Short-term intensive insulin therapy(SIIT) is able to reverse β cell dysfunction and induce glycemic remission in patients with newly diagnosed type 2 diabetes.
- Trial name
- NCT03194945
- Testing
- CSII followed by Lina+MET, CSII followed by Lina, CSII followed by MET
- Where
- China
- Volunteers
- 412 people
- Sponsor
- Sun Yat-sen University
Type 2 Diabetes
Study on Lixisenatide and Counterregulation to Hypoglycemia
In hypoglycemia, there is a counterregulation to restore glucose levels. An important part of this counterregulation is the release of the hormone glucagon.
- Trial name
- NCT02020629
- Testing
- Lixisenatide
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- Lund University